Oncology Discovery at Bristol-Myers Squibb

October 11, 2018

Share :

LabCentral 700

Location: Lobby
Time: 11:30 AM - 2:15 PM

LabCentral sponsor Bristol-Myers Squibb will open its new research facility in Cambridge later this year. With a fully integrated drug discovery and translational medicine organization, the site will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies, and implement our discovery platforms across all of our therapeutic areas of focus (oncology, cardiovascular disease, immunoscience, and fibrosis).

This panel will provide perspectives on the future of oncology therapy, and highlights some of the oncology related goals for BMS overall, and for the new Cambridge site. Other topics on discussion will be the value of being in a vibrant ecosystem, with a focus on their Redwood City, CA, Lawrenceville, NJ, and soon in Cambridge, MA sites. They will examine how these respective sites, and the ecosystems in which they are in, position BMS to leverage biological insights, as well as innovative approaches and technologies, to tackle some of the toughest scientific problems in oncology drug research.

To end they will offer their perspectives on what they love about their work within Bristol-Myers Squibb, what it takes to be a leader in the field, and the types of skills and backgrounds they are looking for as they seek to build an Oncology Discovery organization in Cambridge. Join us for this exciting conversation with Bristol-Myers Squibb’s oncology research leadership!


Moderated by Bruce Car, Vice President, and Head, Translational Medicine Science and Operations

  • Emma Lees, Vice President and Head of Oncology Biology, Cambridge & Small Molecule IO
  • Nils Lonberg, Senior Vice President, Oncology Discovery Biology
  • Mike Quigley, Executive Director, Oncology Discovery Biology


  • 11:30 AM | Registration Opens, Networking and Lunch
  • 12:00 PM | Panel Discussion
  • 1:00 PM | Q&A, Networking
  • 2:15 PM | Program Close